Try our beta test site
5 studies found for:    Open Studies | marginal zone lymphoma | Phase 3
Show Display Options
Rank Status Study
1 Recruiting Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Rituximab;   Drug: Lenalidomide;   Drug: Placebo
2 Recruiting Safety and Efficacy Study of BCD-020 in Therapy of Non-Hodgkin's Lymphoma
Conditions: Follicular Non-Hodgkin's Lymphoma;   Nodal Marginal Zone Lymphoma;   Splenic Marginal Zone Lymphoma
Intervention: Biological: rituximab
3 Not yet recruiting A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Conditions: Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Marginal Zone Lymphoma;   Mucosal-Associated Lymphoid Tissue Lymphoma
Interventions: Dietary Supplement: Vitamin D;   Biological: rituximab;   Other: Placebo
4 Recruiting Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Lenalidomide;   Drug: Rituximab
5 Recruiting Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
Conditions: Follicular Lymphomas;   Immunocytomas;   Marginal Zone Lymphomas;   Mantle-Cell Lymphomas;   Lymphocytic Lymphoma;   Non-Hodgkin's Lymphoma
Interventions: Drug: Rituximab;   Drug: Rituximab / observation

Study has passed its completion date and status has not been verified in more than two years.